Ambrosol syrup: Each 5 ml syrup contains 15 mg Ambroxol Hydrochloride BP.
Ambroxol Hydrochloride is the active metabolite of Bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than Bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol Hydrochloride has anti-inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
Productive cough, acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus, asthmatic bronchitis, bronchial asthma with thick expectoration, bronchiectasis, chronic pneumonia.
Ambrosol syrup.
Ambroxol Hydrochloride should not be taken simultaneously with antitussives (e.g. Codeine) because phlegm, which has been liquefied by Ambroxol, might not be expectorated.
Ambroxol Hydrochloride should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Use in Pregnancy: Teratogenic and foetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the first trimester. Use in Lactation: Safety during lactation has not been established yet.
Store in a cool dry place, protected from light. Keep out of reach of children.